Abstract: The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acids. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agent, a penetration enhancer, and an emulsifier.

Abstract: Two disparate biological mechanisms which predispose to the dissemination and metastases of solid tumors is described.

Abstract: Two disparate biological mechanisms which predispose to the dissemination and metastases of solid tumors is described.

Abstract: A formulation for transdermal delivery of one or more buffering agents through the skin of a subject, comprising: a buffering agent comprising at least one carbonate salt, lysine, tris, a phosphate buffer and/or 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), or a combination thereof in an amount between about 10-56% w/w; and a penetrant portion in an amount between about 44 to 90% w/w, wherein the penetrant portion comprises water in an amount less than about 85% w/w, and wherein the formulation comprises less than about 12% w/w lecithin.

Abstract: Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid minors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.

Abstract: A pet transportation device is provided. The pet transportation device is provided whereby the device is easily adaptable to a mobile unit including a bicycle, scooter and/or motorcycle. In an exemplary embodiment, the pet transportation device has at least a wire basket carrier which is adapted to placement and holding of the pet during transport and at least a cover portion which encloses about the head portion of the pet and may be adapted for folding when not desired by the individual. The basket may be removably attached to at least a portion of the handlebars of a mobile unit by a clamping means and may have padded rail support incorporated thereon. Additionally, the pet transport device may additionally have a liner and/or cushion to protect the limbs of the animal from protruding away from the pet transport device.

Abstract: A pet transportation device is provided. The pet transportation device is provided whereby the device is easily adaptable to a mobile unit including a bicycle, scooter and/or motorcycle. In an exemplary embodiment, the pet transportation device has at least a wire basket carrier which is adapted to placement and holding of the pet during transport and at least a cover portion which encloses about the head portion of the pet and may be adapted for folding when not desired by the individual. The basket may be removably attached to at least a portion of the handlebars of a mobile unit by a clamping means and may have padded rail support incorporated thereon. Additionally, the pet transport device may additionally have a liner and/or cushion to protect the limbs of the animal from protruding away from the pet transport device.

Abstract: An improved composition for treatment of the skin comprises: (1) methionine and cysteine in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (2) a mixture of essential amino acids in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin, the mixture comprising isoleucine, leucine, lysine, phenylalanine, threonine, tryptophan, valine, histidine, and arginine; (3) at least one antioxidant in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (4) at least one cross-linking agent in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (5) at least one metallic catalyst in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (6) at least one transepidermal delivery agent in a quantity sufficient to promote delivery of the composition to the skin; and (7) a topical pharmaceutically acceptable carrier.